Is Viking Therepautics a Buy Now?

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the company showed the medical community and investors results that suggest its experimental anti-obesity tablet, tentatively named VK2735, could go on to generate blockbuster sales.

Viking's previous positive results for the experimental treatments in its pipeline haven't gone unnoticed by the overall stock market. The stock has risen about 256% in 2024.

Let's look at the latest trial results from Viking Therapeutics to see if it's a smart buy now despite already soaring this year.

Source Fool.com